Ocuclear

Quick links to important sections

Ocuclear

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ocuclear

What is Ocuclear? Identity and Classification

Property Description
Active ingredient Oxymetazoline Hydrochloride
Form Ophthalmic Solution
Pharmacological Class Alpha-adrenergic Agonist / Vasoconstrictor
Common General Purpose Reduction of visible eye redness
Origin Synthetic Compound

Ocuclear is a medicinal preparation whose identity is defined by its active ingredient, Oxymetazoline Hydrochloride, a synthetic compound formulated as an ophthalmic solution for topical application. This drug is classified as a sympathomimetic amine and a direct-acting vasoconstrictor.

What is the Composition and Class of Ocuclear?

The core component of Ocuclear is Oxymetazoline Hydrochloride, which is the sole active ingredient, classifying it as a single-ingredient product. This substance belongs to the alpha-adrenergic agonist pharmacological group, meaning it is engineered to specifically target and stimulate particular receptors in the body. Oxymetazoline is chemically a synthetic derivative, belonging to the Imidazole chemical class, confirming its non-natural origin. The preparation itself is an ophthalmic solution, meaning the active compound is dissolved in a sterile, aqueous vehicle formulated to be suitable for direct application to the eye surface, meeting standards for ocular purity.

How is Ocuclear Classified as a Vasoconstrictor?

Ocuclear is classified as a vasoconstrictor because its fundamental mechanism is to cause the temporary narrowing of blood vessels at the site of application. It is defined as a sympathomimetic agent due to its ability to mimic the effects of endogenous substances on the sympathetic nervous system. This physiological action serves the general purpose of reducing the appearance of eye redness. For instance, it is typically used to manage redness resulting from minor irritations. The efficacy of Oxymetazoline for this purpose is clinically recognized within pharmacological studies. By prompting the temporary constriction of the visibly engorged vessels within the conjunctiva, the solution diminishes the reddened state, which is the immediate, non-specific benefit provided by the medicine.

Regulatory References

  1. DailyMed

What side effects are possible with Ocuclear?

Possible Side Effects and Safety Information

The officially documented safety profile of Ocuclear (Oxymetazoline Hydrochloride ophthalmic solution) is structured around adverse reactions categorized by frequency and the potential for systemic effects under certain conditions. The majority of known side effects are local and classified as Common, meaning they occurred with an incidence of 1% to 5% in clinical trials according to regulatory standards.


Adverse Reactions and Systemic Constraints

Classification Examples of Officially Documented Effects
Common Ocular Effects Eye irritation, dry eye, punctate keratitis, vision blurred, and instillation site pain.
Common Systemic Effects Headache.

Serious Adverse Reaction Context

Official regulatory documents highlight the potential risk of angle-closure glaucoma in individuals with untreated narrow-angle glaucoma. Furthermore, accidental ingestion of this solution, particularly by children, is documented as a cause of severe adverse events, including central nervous system depression, decreased heart rate, and coma, requiring immediate emergency response.

Population and Exposure-Related Safety Notes

Safety constraints advise caution for individuals with certain pre-existing systemic conditions, including severe or unstable cardiovascular disease, uncontrolled hypertension, cerebral or coronary insufficiency, and prostatic enlargement. Caution is also advised when co-administering the product with certain drug classes, such as Monoamine Oxidase Inhibitors (MAOIs), as the product belongs to a class of medications that may impact blood pressure. Prolonged or frequent use is noted to potentially increase systemic absorption and the subsequent risk of systemic effects.

Overdose and Emergency Response

Ocuclear Overdose and when to seek help

Documented Overdose Manifestations

Overdose of Ocuclear (Oxymetazoline Hydrochloride) primarily affects the Central Nervous System (CNS) and the Cardiovascular System due to systemic absorption of the vasoconstrictor. Documented CNS effects include somnolence, tremors, and severe depression, which may escalate to stupor or coma. Cardiovascular manifestations listed in regulatory documents include fluctuations in blood pressure, from hypertension to severe hypotension, as well as cardiac arrhythmia and palpitations. Other documented signs include mydriasis (pupil dilation) and gastrointestinal symptoms like nausea and vomiting.


Mandatory Emergency Response

The regulatory profile explicitly highlights a Pediatric Risk Warning: accidental oral ingestion by young children (five years of age and under) is a high-risk scenario that can cause serious adverse events, including decreased heart rate, apnoea, and coma, often requiring hospitalization. Treatment is specified as symptomatic and supportive because official labeling confirms that no specific antidote is known. For any suspected overdose or accidental ingestion, immediate medical attention must be sought, and the national Poison Help Line should be contacted without delay. Management requires close monitoring of vital signs.

Therapeutic Uses of Ocuclear

What Ocuclear Treats: Main Uses and Benefits

Ocuclear (Oxymetazoline Hydrochloride ophthalmic solution) is applied across domains where additional symptomatic support is needed for symptoms linked to organ-specific functional stress in the eye, particularly visible vascular congestion. The primary therapeutic domain of the active ingredient is used in areas where short-term symptom management is appropriate for minor eye irritations.

Symptomatic Relief for Visible Redness

Ocuclear is commonly used to help with symptoms related to physical discomfort, is applied in addressing visible eye redness (conjunctival hyperemia). It plays a role in managing symptom clusters that may become intense or disruptive, such as those associated with minor eye irritations, redness from environmental exposure, and eye fatigue. It contributes to easing the overall symptom load by supporting the management of symptoms that create noticeable physiological strain.

Use in Episodic Scenarios

The medication is applied in settings marked by temporary physiological imbalance, such as those arising from common environmental triggers (like dust, wind, or swimming) or lifestyle factors (like prolonged screen use). The therapeutic benefit offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Ocular Congestion

Ocuclear is primarily used to provide short-term symptomatic assistance for the visible effects of ocular congestion stemming from minor, external triggers.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ocuclear?

Eligibility to use Ocuclear (Oxymetazoline Hydrochloride ophthalmic solution) is defined by official regulatory documents, strictly based on age, pre-existing health conditions, and drug interactions.


Category Official Regulatory Status
Populations Contraindicated Patients with known hypersensitivity to any ingredient, or those receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI treatment.
Age-Related Eligibility Use is established in adults and adolescents 13 years of age and older. Safety and effectiveness have not been established for children under 13.
Conditional Use (Caution) Caution is advised for patients with severe or unstable cardiovascular disease, uncontrolled hypertension, untreated narrow-angle glaucoma, hyperthyroidism, hyperglycemia (diabetes mellitus), or Sjögren's Syndrome.
Pregnancy/Lactation Pregnancy: Human data are not available to determine drug-associated risk. Lactation: Caution is advised; it is not known if the drug is excreted in human milk.

Official documents mandate that the medicine must not be used by individuals with certain drug incompatibilities or allergies. Use in adults is subject to caution regarding specific comorbidities due to the drug's alpha-adrenergic agonist properties, which may affect systemic circulation. The established eligibility profile does not include children under 13, as regulatory authorities have not established safety and effectiveness in that age group.

What should I know about interactions with other medicines?

Ocuclear (oxymetazoline ophthalmic) has the potential to interact with a wide range of other medicines due to its sympathomimetic property, which is characterized by its effect as an alpha-adrenergic agonist.

Documented Interaction Profile

The official interaction profile is characterized by the following medicinal product categories, where co-administration may require caution, dose modification, or avoidance:

Product Category Interaction Implication
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use is not recommended due to the potential for hypertensive crisis (severely high blood pressure).
Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution is advised when used with medicines such as beta-blockers and cardiac glycosides (e.g., digoxin).
Tricyclic Antidepressants Use with caution, as this combination may potentiate the sympathomimetic effects of oxymetazoline, leading to elevated blood pressure.

Official regulatory information classifies the overall known drug interaction profile as encompassing 138 interactions, with 6 Major and 132 Moderate classifications. Major interactions are considered highly clinically significant, with the risk typically outweighing the benefit, necessitating that these combinations generally be avoided.

Interaction-Related Constraints

The product's systemic absorption creates the potential for blood vessel problems and changes in blood pressure (too high or too low). Patients should not take any other prescription or non-prescription (OTC) medicines, herbal products, or vitamin supplements without first consulting a healthcare professional. If other eye medicines are being used, it is advised to wait at least 15 minutes after applying this product before using the other ophthalmic preparations.

Mechanism of Action

Alpha-Adrenergic Agonism and Local Vasoconstriction

Ocuclear’s action is defined by a specific pharmacodynamic mechanism, centered on the direct stimulation of defined adrenergic receptors to modulate local vascular tone. The molecule acts as a direct-acting agonist that preferentially stimulates postsynaptic alpha1-adrenergic receptors found on the vascular smooth muscle. This interaction initiates the contraction of the vessel walls, leading to localized vasoconstriction. This physiological narrowing of the superficial blood vessels determines the decrease in the volume of blood pooled in the outer eye tissues.

Gq Cascade, Calcium Mobilization, and Onset

The alpha1-receptor activation triggers the coupled Gq protein signaling cascade. This molecular sequence results in a rapid mobilization of calcium ions ( Ca^2+) inside the vascular smooth muscle cells. The Ca^2+-driven muscle contraction allows for a quick and localized adjustment of the vessel diameter, directly contributing to the drug's rapid onset of the physiological effect.

Mechanism Limitations and Feedback Regulation

Though applied for acute modulation, prolonged stimulation of the alpha1-adrenergic receptors can lead to receptor desensitization (tachyphylaxis). Furthermore, the physiological system's attempt to restore balance can trigger rebound hyperemia—a subsequent increase in vasodilation beyond baseline levels upon the drug's discontinuation. These are mechanism-dependent consequences of the body's natural feedback regulation against continuous external constraint.

Dosage and Administration Information

How Ocuclear is Used

Ocuclear (Oxymetazoline Hydrochloride ophthalmic solution) is administered by topical instillation to the surface of the eye, following distinct protocols based on the specific concentration utilized. The instructions for use are defined by the required strength, frequency, and duration of the regimen.


Administration Guidelines

Feature Labeled Instruction
Route of Administration Topical (Ophthalmic)
Dosing Schedule (0.1% Strength) One drop in the affected eye(s)
Dosing Schedule (0.025% Strength) 1 or 2 drops in the affected eye(s)
Frequency Pattern Once daily for the 0.1% strength; Up to four times daily (as needed) for the 0.025% strength
Duration Constraint The 0.025% solution is generally limited to short-term use; the 0.1% strength is used daily in long-term regimens
Age Restriction (0.1% Strength) Approved for patients 13 years of age and older
Age Restriction (0.025% Strength) Approved for children 6 years of age and older

Procedural Administration Rules

The established usage protocol requires the temporary removal of soft contact lenses before the solution is applied. The instructions specify that lenses may be reinserted 15 minutes after administration. To prevent potential contamination, the applicator tip must not contact the eye or any external surface. If multiple topical ophthalmic products are prescribed, the guidance requires an interval of at least 15 minutes between instillation of Ocuclear and other drops. If a dose is missed for the once-daily regimen (0.1% strength), the protocol is to continue with the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has investigated the study drug's role in the management of migraines, specifically exploring its impact on frequency and severity. Studies evaluated whether the use of the study drug was associated with a reduction in migraine days per month and measures of quality of life.


Key Efficacy Findings

Studies have investigated the study drug in patient populations experiencing both episodic and chronic migraine. One large-scale Phase 3 study observed that 75% of participants with chronic migraine met the criteria for improved quality of life. This outcome was assessed using the Migraine-Specific Quality of Life Questionnaire (MSQ).

Outcome Type Study Evaluation Focus
Episodic Migraine Reduction in mean monthly migraine days compared to a placebo group.
Chronic Migraine Proportion of participants achieving a 50% or greater reduction in monthly migraine days.

Studies have examined whether the study drug's administration was associated with a rapid onset of change and a prolonged decrease in the number of migraine days per month. Studies also explored whether the co-administration of the study drug and over-the-counter pain relievers was associated with an impact on attack-related symptoms.


Adverse Events and Tolerability

Research was conducted to evaluate adverse events and tolerability in adult populations. In clinical trials, the most frequent events reported included injection site reactions, constipation, and muscle cramps.

Several studies included long-term monitoring of patient experience. Early trials included evaluation of potential cardiovascular events; specific patient groups were not enrolled in some studies.

Key Studies & References Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine (Retrospective Cohort Study)

Frequently Asked Questions (FAQ)

Common questions about Ocuclear (FAQ)

Q: What is the main reason doctors prescribe Ocuclear?

A: Ocuclear (0.1% strength) is a prescription medicine officially indicated for the treatment of acquired blepharoptosis, which is a condition causing a low-lying or droopy upper eyelid in adults. This core purpose is established in regulatory documents defining the drug’s primary approved use.

Q: Is Ocuclear used to treat conditions other than the main one listed?

A: The prescription strength (0.1%) of Ocuclear is indicated only for treating acquired blepharoptosis. However, a lower, over-the-counter concentration (0.025%) of the same active ingredient is widely available and approved for the temporary relief of minor eye redness. Official regulatory information specifies these distinct uses based on the drug's strength.

Q: Why is Ocuclear only available by prescription?

A: The active ingredient, Oxymetazoline, is available in both over-the-counter (OTC) and prescription forms. The 0.1% concentration used for treating droopy eyelids is specifically approved as a prescription drug due to its particular intended effect and required clinical oversight. The lower concentration OTC version is approved for temporary relief of minor eye redness.

Q: Do I need to change my diet while using Ocuclear?

A: Official regulatory documents and patient information state that there are no known interactions between the drug and specific foods or drinks. Official documents state that no mandatory dietary changes are required with the use of this medication.

Q: Is it normal to feel a little dizzy after starting Ocuclear?

A: Dizziness is a side effect reported in regulatory documents. This effect is linked to the drug's potential to affect blood pressure, which may cause headaches, lightheadedness, or dizziness. Official information notes that the drug's effect on blood pressure may lead to such systemic effects.

Q: Is Ocuclear considered a narcotic or controlled substance?

A: According to the United States Drug Enforcement Administration (DEA) and official regulatory records, Ocuclear (Oxymetazoline Hydrochloride ophthalmic solution) is not a federally controlled substance. It is not associated with abuse potential.

Q: Are there any common supplements that interact with Ocuclear?

A: Due to its mechanism, Ocuclear has the potential to interact with other medicines and supplements that affect the cardiovascular system. Regulatory documents include information on the potential for interactions with all prescription, OTC, vitamin, mineral, and herbal products. The official guidance emphasizes that patients should share this information with a prescribing clinician.

Q: How long does the effect of Ocuclear last after the final use?

A: Clinical studies supporting the drug's approval indicate that the intended eyelid lifting effect is typically observed for at least 6 hours following administration. The terminal half-life of the medication in the body, which describes the time it takes for the concentration to reduce by half, is documented as approximately 8.3 hours.

Q: Can people over the age of 65 use Ocuclear?

A: Official regulatory information states that studies performed have not demonstrated geriatric-specific problems that would automatically limit the drug's use solely based on age. However, caution is advised for all patients, including older adults, who have pre-existing cardiovascular conditions such as severe cardiovascular disease or uncontrolled high blood pressure.

Q: How does Ocuclear relate to the condition it treats?

A: Ocuclear works by activating specific alpha-adrenergic receptors. This activation causes muscle contraction in the eyelid, which results in the lifting of the upper eyelid. This localized muscle contraction is the specific mechanism that addresses the symptoms of acquired blepharoptosis (droopy eyelid).

Q: Is Ocuclear safe to use for people with kidney problems?

A: Official regulatory documentation does not provide specific warnings or dose adjustments for kidney conditions. Regulatory information notes that the drug is only minimally processed by the liver, and the exact process of its elimination from the body has not been fully characterized. Consultation with a healthcare professional regarding your condition is advised.

Q: Does Ocuclear make you drowsy?

A: Drowsiness (somnolence) is not listed among the common adverse reactions documented in the official regulatory prescribing information for Ocuclear.

Q: How many people participated in the main clinical trials for Ocuclear?

A: The efficacy and safety of the 0.1% prescription solution were evaluated in multiple clinical trials. The primary studies included over 350 subjects who received the drug once daily over a six-week period.

Q: Can Ocuclear be taken with common pain relievers like ibuprofen?

A: The drug’s official label does not specifically name common non-prescription pain relievers like ibuprofen as a known interaction. Regulatory information advises that all non-prescription medicines be reviewed by a healthcare professional to assess for potential interactions before use.

Q: Is Ocuclear addictive?

A: The prescription version of Ocuclear is not classified as a controlled substance by regulatory bodies and is not associated with abuse potential or addiction.

Q: Can people with liver disease use Ocuclear?

A: Regulatory information indicates that the drug is only minimally metabolized (processed) by the liver. No specific dose adjustment or contraindication is noted for liver disease. Consultation with a healthcare professional regarding your complete medical history is recommended.

Q: Does Ocuclear affect my ability to drive or operate machinery?

A: The official safety profile lists blurred vision as a common side effect. Because this can temporarily impair your vision, official guidance notes that patients should avoid driving or operating heavy machinery until blurred vision clears, as this side effect is documented in the product's safety profile.

Q: Is it safe to drink alcohol in moderation while using Ocuclear?

A: Official regulatory documents do not contain known interactions between the active ingredient in the prescription strength of Ocuclear and alcohol consumption. The official label does not document any known interactions between the active ingredient and alcohol consumption.

Q: Are there any specific foods that must be avoided with Ocuclear?

A: Based on official regulatory information, there are no known interactions between Ocuclear and specific foods. You do not have to avoid any particular food or food group while using this product.

Q: Does Ocuclear have any known long-term side effects?

A: The common and serious adverse reactions are detailed in the official safety information. While clinical trials included long-term monitoring, the drug’s labeling does not detail a unique set of long-term side effects beyond the potential for rebound hyperemia (increased redness/swelling) if use is suddenly discontinued.

Q: Is there a specific time of day Ocuclear is usually taken?

A: The prescription dose (0.1% strength) is instructed to be administered once daily to the affected eye(s). Official guidelines do not specify a certain time of day, allowing the patient and their healthcare professional to integrate the dose into their daily routine.

How should Ocuclear be stored and disposed of?

How to Store and Dispose of Ocuclear

Ocuclear (oxymetazoline ophthalmic solution) must be stored according to official regulatory requirements to maintain its stability and ensure patient safety.


Storage Requirements

The medication is required to be stored at room temperature, typically between 68 F to 77 F (20 C to 25 C). It is mandatory to keep the product from freezing and protect it from excessive heat, moisture, and direct light. The container must be kept tightly closed and stored in its original, child-resistant foil pouch until use.

Ocuclear, like all medicines, must be kept out of the reach of children.


Stability and Disposal

Due to its single-use format, the container and any unused solution must be discarded immediately after dosing. Outdated or unneeded medication should not be kept. Regulatory instructions direct the user to ask a healthcare professional for guidance on the proper disposal of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ocuclear found in:

A-Z Index: